News: Latest News

Code Biotherapeutics, Inc. (Code Bio), a biotechnology company pioneering the targeted delivery of precision genetic medicines, today announces the appointment of Alex Tracy, PhD, as Chief Technical Officer.

Code Biotherapeutics, Inc. (Code Bio), a biotechnology company pioneering targeted non-viral delivery of genetic medicines, today announces the appointment of David Anderson, PhD, as Chief Scientific Officer.

Code Biotherapeutics, Inc. (Code Bio), a biotechnology company pioneering targeted non-viral delivery of genetic medicines, today announced a collaboration and option agreement with Takeda to leverage Code Bio’s proprietary targeted 3DNA® non-viral genetic medicine delivery platform to design and develop gene therapies for rare disease indications.

Code Biotherapeutics, Inc. (Code Bio), a biotechnology company pioneering targeted non-viral delivery of genetic medicines, today announced a collaboration and option agreement with Takeda to leverage Code Bio’s proprietary targeted 3DNA® non-viral genetic medicine delivery platform to design and develop gene therapies for rare disease indications.

Code Biotherapeutics, Inc., a biotechnology company pioneering targeted non-viral delivery of genetic medicines, announces the appointment of Erin Brubaker as Chief Operating Officer, effective immediately.

Code Biotherapeutics, Inc., a next-generation gene therapy company pioneering the development of targeted non-viral gene therapies for rare and prevalent genetic diseases, launches today with $10 million in financing and headquarters in the Philadelphia region’s leading gene therapy epicenter.

Code Biotherapeutics, Inc., a next-generation gene therapy company pioneering the development of targeted non-viral gene therapies for rare and genetic diseases, announces today that Lauren M. Kaskiel, MBA will join the company as its Chief Business Officer.